Antiplatelet and Lipid-lowering Drugs in Hypertension

Area of Science:

• Cardiology
• Pharmacology
• Nephrology
• Obstetrics

Background:

• Hypertension management involves considering antiplatelet therapy, particularly low-dose acetylsalicylic acid (ASA).
• Guidelines recommend ASA for specific high-risk hypertensive patients, while cautioning against its use in lower-risk groups.
• Statins offer cardiovascular benefits and a modest blood pressure-lowering effect, with guideline-directed lipid targets for hypertensive patients.

Purpose of the Study:

• To review the current recommendations for antiplatelet therapy, specifically ASA, in hypertensive patients.
• To discuss the role of ASA in pregnant women at risk of pre-eclampsia.
• To outline the use of statins in hypertensive patients based on cardiovascular risk and lipid targets.

Main Methods:

• Review of existing clinical guidelines and recommendations from the European Society of Hypertension (ESH) and European Society of Cardiology (ESC).
• Analysis of the evidence supporting the use and non-use of acetylsalicylic acid in different hypertensive patient populations.
• Examination of the benefits of statins, including their impact on blood pressure and lipid levels.

Main Results:

• Low-dose ASA is recommended for hypertensive patients with previous cardiovascular events, reduced renal function, or high cardiovascular risk, provided blood pressure is controlled.
• ASA is not advised for hypertensive patients at low-to-moderate risk where benefits and harms are balanced.
• Statins are recommended for hypertensive patients at moderate-to-high cardiovascular risk to achieve specific LDL cholesterol targets.

Conclusions:

• The use of antiplatelet therapy, including ASA, in hypertension requires careful risk stratification.
• Further research into novel antithrombotic agents for hypertension is necessary.
• Low-dose ASA is advised for pregnant women at high and moderate risk of pre-eclampsia.